HIM
ANAC

Hillsdale Investment Management’s ANACOR PHARMACEUTICALS INC COM ANAC Stock Holding History

Hillsdale Investment Management’s Portfolio ANAC Stock Details ANAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-1,700
Closed -$200K – 651
2015
Q3 		$200K Buy
+1,700
New +$222K 0.07% 306

Other funds holding ANAC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Hillsdale Investment Management's ANAC Position: Q4 2015 in Review

Hillsdale Investment Management sold out of ANACOR PHARMACEUTICALS INC COM (ANAC) in Q4 2015, closing a stake of 1,700 shares — an estimated $200K sold.

Hillsdale Investment Management first reported a position in ANAC in Q3 2015 and held it in 1 quarter. The position peaked at $200K in Q3 2015. 214 funds tracked by Wall St. Rank hold ANAC as of Q4 2015.

  • Hillsdale Investment Management reported no remaining ANACOR PHARMACEUTICALS INC COM position as of Q4 2015 after selling out during the quarter.
  • Hillsdale Investment Management sold 1,700 ANACOR PHARMACEUTICALS INC COM shares in Q4 2015, an estimated $200K.
  • Hillsdale Investment Management first reported a position in ANACOR PHARMACEUTICALS INC COM in Q3 2015 and held it in 1 quarter.
  • Hillsdale Investment Management's ANACOR PHARMACEUTICALS INC COM position peaked at $200K in Q3 2015.
  • 214 funds tracked by Wall St. Rank held ANACOR PHARMACEUTICALS INC COM as of Q4 2015.

Based on Hillsdale Investment Management's 13F filing for Q4 2015, filed 4 Feb 2016.